Hutchison China MediTech Limited Company Profile (LON:HCM)

About Hutchison China MediTech Limited (LON:HCM)

Hutchison China MediTech Limited logoHutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures markets and distributes prescription drugs and consumer health products in China.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Alternative Medicine
  • Sub-Industry: N/A
  • Symbol: LON:HCM
  • CUSIP: N/A
  • Web: www.chi-med.com/
Capitalization:
  • Market Cap: £2.55 billion
  • Outstanding Shares: 60,681,000
Average Prices:
  • 50 Day Moving Avg: GBX 4,003.45
  • 200 Day Moving Avg: GBX 6,090.11
  • 52 Week Range: GBX 1,810 - GBX 4,575
P/E:
  • Trailing P/E Ratio: 209.67
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £238.15 million
  • Price / Sales: 10.70
  • Book Value: GBX 3.12 per share
  • Price / Book: 13.46
Profitability:
  • EBITDA: ($44,320,000.00)
  • Net Margins: 2.91%
  • Return on Equity: 1.80%
  • Return on Assets: 2.14%
Misc:
  • Average Volume: 11,753 shs.
 

Frequently Asked Questions for Hutchison China MediTech Limited (LON:HCM)

What is Hutchison China MediTech Limited's stock symbol?

Hutchison China MediTech Limited trades on the London Stock Exchange (LON) under the ticker symbol "HCM."

Where is Hutchison China MediTech Limited's stock going? Where will Hutchison China MediTech Limited's stock price be in 2017?

2 analysts have issued 1-year price objectives for Hutchison China MediTech Limited's stock. Their predictions range from GBX 3,840 to GBX 3,840. On average, they expect Hutchison China MediTech Limited's share price to reach GBX 3,840 in the next year. View Analyst Ratings for Hutchison China MediTech Limited.

Who are some of Hutchison China MediTech Limited's key competitors?

Who are Hutchison China MediTech Limited's key executives?

Hutchison China MediTech Limited's management team includes the folowing people:

  • Simon To, Executive Chairman of the Board
  • Christian Hogg, Chief Executive Officer, Executive Director
  • Chig Fung Cheng, Chief Financial Officer, Executive Director
  • Weiguo Su Ph.D., Executive Director
  • Edith Shih, Company Secretary, Non-Executive Director
  • Dan Eldar, Non-Executive Director
  • Paul Rutherford Carter, Senior Independent Non-Executive Director
  • Karen Jean Ferrante M.D., Non-Executive Independent Director
  • Graeme Allan Jack, Independent Non-Executive Director

How do I buy Hutchison China MediTech Limited stock?

Shares of Hutchison China MediTech Limited and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hutchison China MediTech Limited's stock price today?

One share of Hutchison China MediTech Limited stock can currently be purchased for approximately GBX 4,200.


MarketBeat Community Rating for Hutchison China MediTech Limited (LON HCM)
Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  35 (Vote Underperform)
Total Votes:  159
MarketBeat's community ratings are surveys of what our community members think about Hutchison China MediTech Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Hutchison China MediTech Limited (LON:HCM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 3,840
Consensus Price Target History for Hutchison China MediTech Limited (LON:HCM)
Price Target History for Hutchison China MediTech Limited (LON:HCM)
Analysts' Ratings History for Hutchison China MediTech Limited (LON:HCM)
Show:
DateFirmActionRatingPrice TargetDetails
8/29/2017Panmure GordonReiterated RatingBuyGBX 3,840View Rating Details
8/1/2017Beaufort SecuritiesReiterated RatingBuyView Rating Details
4/11/2016Stifel NicolausInitiated CoverageBuyView Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for Hutchison China MediTech Limited (LON:HCM)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Hutchison China MediTech Limited (LON:HCM)
Current Year EPS Consensus Estimate: $-0.25 EPS

Dividends

Dividend History for Hutchison China MediTech Limited (LON:HCM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Hutchison China MediTech Limited (LON:HCM)
Insider Trades by Quarter for Hutchison China MediTech Limited (LON:HCM)
Insider Trades by Quarter for Hutchison China MediTech Limited (LON:HCM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2017Karen Jean FerranteInsiderBuy10,000GBX 3,475£347,500
3/15/2017Paul Rutherford CarterInsiderBuy2,800GBX 2,637£73,836
11/21/2016Michael HowellInsiderSell3,000GBX 1,890£56,700
10/28/2016Michael HowellInsiderSell2,500GBX 1,860£46,500
10/26/2016Michael HowellInsiderSell3,000GBX 1,850£55,500
10/25/2016Michael HowellInsiderSell1,000GBX 1,840£18,400
10/24/2016Michael HowellInsiderSell339GBX 1,825£6,186.75
10/7/2016Michael HowellInsiderSell15,000GBX 1,790£268,500
8/4/2016Nash,ChristopherInsiderBuy42GBX 1,899£797.58
10/20/2015Nash,ChristopherInsiderBuy4,512GBX 2,195£99,038.40
4/21/2015Christopher NashInsiderBuy1,388GBX 1,800£24,984
4/15/2015Simon ToInsiderBuy28,000GBX 1,585£443,800
4/10/2015Simon ToInsiderBuy25,000GBX 1,421.50£355,375
4/7/2015Edith ShihInsiderBuy2,000GBX 1,385£27,700
4/2/2015Simon ToInsiderBuy10,000GBX 1,385£138,500
4/1/2015Edith ShihInsiderBuy15,000GBX 1,365£204,750
3/30/2015Edith ShihInsiderBuy13,000GBX 1,300£169,000
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Hutchison China MediTech Limited (LON:HCM)
Latest Headlines for Hutchison China MediTech Limited (LON:HCM)
Source:
DateHeadline
businesswire.com logoChi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer - Business Wire (press release)
www.businesswire.com - October 18 at 1:07 AM
finance.yahoo.com logoChi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification
finance.yahoo.com - October 17 at 2:04 AM
streetinsider.com logoForm 6-K Hutchison China MediTech For: Oct 16 - StreetInsider.com
www.streetinsider.com - October 16 at 9:04 PM
businesswire.com logoHutchison China MediTech: Appointment of Director - Business Wire (press release)
www.businesswire.com - October 12 at 5:32 AM
finance.yahoo.com logoHutchison China MediTech: Appointment of Director
finance.yahoo.com - October 12 at 5:32 AM
finance.yahoo.com logoEdited Transcript of HCM.L earnings conference call or presentation 31-Jul-17 8:00am GMT
finance.yahoo.com - October 4 at 2:38 PM
finance.yahoo.com logoHutchison China MediTech Ltd. – Value Analysis (LONDON:HCM) : September 26, 2017
finance.yahoo.com - September 26 at 4:26 PM
finance.yahoo.com logoHutchison China MediTech Ltd. breached its 50 day moving average in a Bearish Manner : HCM-GB : September 25, 2017
finance.yahoo.com - September 25 at 10:17 AM
lse.co.uk logoDirector's Share Dealing - London South East (registration) (blog)
www.lse.co.uk - August 31 at 7:19 PM
streetinsider.com logoHutchison China MediTech (HCM) Initiates Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL-689 in Lymphoma - StreetInsider.com
www.streetinsider.com - August 31 at 7:19 PM
nasdaq.com logoChi-Med Initiates a Phase I Clinical Trial of Selective PI3Kd Inhibitor HMPL-689 in Lymphoma Patients in China
www.nasdaq.com - August 29 at 7:54 PM
morningstar.co.uk logoHutchison China Meditech Starts Phase One Trial For Lymphoma Treatment
www.morningstar.co.uk - August 29 at 7:54 PM
streetinsider.com logoHutchison China MediTech (HCM) Initiates Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL-689 in Lymphoma
www.streetinsider.com - August 29 at 7:54 PM
americanbankingnews.com logoHutchison China MediTech Limited's (HCM) "Buy" Rating Reiterated at Panmure Gordon
www.americanbankingnews.com - August 29 at 7:24 AM
finance.yahoo.com logoChi-Med Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL-689 in Lymphoma Patients in China
finance.yahoo.com - August 29 at 5:04 AM
morningstar.co.uk logoDIRECTOR DEALINGS: Zenith Energy CEO Cattaneo Increases Stake
www.morningstar.co.uk - August 23 at 12:58 AM
morningstar.co.uk logoDIRECTOR DEALINGS: Hutchison China MediTech Non-Executive Buys ADSs
www.morningstar.co.uk - August 22 at 7:56 PM
finance.yahoo.com logoHutchison China MediTech Ltd. :HCM-GB: Earnings Analysis: For the six months ended June 30, 2017 : August 9, 2017
finance.yahoo.com - August 9 at 12:07 AM
americanbankingnews.com logoInsider Buying: Hutchison China MediTech Limited (HCM) Insider Purchases 10,000 Shares of Stock
www.americanbankingnews.com - August 7 at 7:28 AM
seekingalpha.com logoHutchison China MediTech Limited's (HCM) CEO Christian Hogg on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 6 at 6:03 PM
businesswire.com logoChi-Med Reports 2017 Interim Results and Updates Shareholders ... - Business Wire (press release)
www.businesswire.com - July 31 at 3:15 PM
americanbankingnews.com logoHutchison China MediTech Limited (LON:HCM) Set to Announce Earnings on Sunday
www.americanbankingnews.com - July 23 at 4:26 AM
americanbankingnews.com logoHutchison China MediTech Limited's (LON:HCM) Buy Rating Reaffirmed at Beaufort Securities
www.americanbankingnews.com - July 1 at 1:50 PM
businesswire.com logoChi-Med to Announce 2017 Half-Year Financial Results - Business Wire (press release)
www.businesswire.com - July 1 at 12:33 AM
businesswire.com logoChi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma - Business Wire (press release)
www.businesswire.com - June 29 at 5:01 AM
businesswire.com logoChi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO
www.businesswire.com - June 5 at 8:43 PM
streetinsider.com logoChi-Med (HCM) to Present Clinical Data at ASCO - StreetInsider.com
www.streetinsider.com - May 19 at 10:09 AM
prnewswire.com logoEdison Issues Outlook on Hutchison China MediTech (HCM)
www.prnewswire.com - May 11 at 6:14 PM
reuters.com logoBRIEF-Hutchison China Meditech Ltd says may offer to sell in one or more offerings ADS representing ordinary shares
www.reuters.com - April 3 at 1:23 PM
seekingalpha.com logoHutchison China Meditech (HCM) Presents At Deutsche Bank Depositary Receipts Virtual Investor Conference - Slideshow
seekingalpha.com - March 24 at 5:43 PM
finance.yahoo.com logoChi-Med: Grant of Awards under Long Term Incentive Plan
au.finance.yahoo.com - March 16 at 3:42 PM
biz.yahoo.com logoFull Year 2016 Hutchison China MediTech Ltd Earnings Release - 03:00 am ET
biz.yahoo.com - March 13 at 11:09 AM
uk.finance.yahoo.com logoChi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of European Neuroendocrine Tumor Society
uk.finance.yahoo.com - March 10 at 10:14 AM
ft.com logo[$$] Chi-Med eyes global markets after cancer trial success
www.ft.com - March 3 at 5:37 PM
seekingalpha.com logoChi-Med Looks Outside Its Comfort Zone - Seeking Alpha
seekingalpha.com - February 22 at 5:47 PM
uk.finance.yahoo.com logoChi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma
uk.finance.yahoo.com - February 20 at 10:50 AM
streetinsider.com logoForm SC 13G Hutchison China MediTech Filed by: CK Hutchison Holdings Ltd
www.streetinsider.com - February 8 at 6:17 PM
finanznachrichten.de logoHUTCHISON CHINA MEDITECH LIMITED
www.finanznachrichten.de - February 1 at 4:23 AM
streetinsider.com logoHutchison China MediTech (HCM) Begins Phase 1 Of HMPL-523 Clinical Trials In China On Patients With Hematological Malignancies
www.streetinsider.com - January 10 at 4:24 AM
streetinsider.com logoHutchison China MediTech (HCM) Begins Phase 1 Of HMPL-523 Clinical Trials In China On Patients With ... - StreetInsider.com
www.streetinsider.com - January 10 at 4:24 AM
bloomberg.com logoChina’s Airpocalypse Paves a Path for New Cancer Medicines
www.bloomberg.com - January 5 at 6:36 PM
streetinsider.com logoForm 6-K Hutchison China MediTech For: Dec 31 - StreetInsider.com
www.streetinsider.com - December 30 at 6:02 PM
finance.yahoo.com logoChi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting
au.finance.yahoo.com - December 6 at 10:38 AM
businesswire.com logoChi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting - Business Wire (press release)
www.businesswire.com - November 14 at 9:28 AM
uk.finance.yahoo.com logoChi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting
uk.finance.yahoo.com - November 14 at 9:28 AM

Social

Social activity is not available for this stock.

Chart

Hutchison China MediTech Limited (HCM) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.